Eisai and Pfizer received FDA approval for an sNDA for Aricept for the treatment of severe Alzheimer’s disease (AD). With this approval, Aricept becomes the only prescription medication to treat mild, moderate and severe AD. Aricept, which is co-promoted in the U.S. by Eisai and Pfizer, has been approved in the U.S. since 1996 for treatment of mild to moderate AD. The approval was based on results from a multi-center, randomized, double-blind, placebo-controlled trial involving 248 p...